Santavicca M, Noel A, Angliker H, Stoll I, Segain J P, Anglard P, Chretien M, Seidah N, Basset P
Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Centre National de la Recherche Scientifique/Institut National de la Santé et de la Recherche Médicale U184/Université Louis Pasteur, C.U. de Strasbourg, France.
Biochem J. 1996 May 1;315 ( Pt 3)(Pt 3):953-8. doi: 10.1042/bj3150953.
Stromelysin-3 (ST3) is a matrix metalloproteinase (MMP) which has been implicated in cancer progression and in a number of conditions involving tissue remodelling. In contrast to other MMPs which are secreted as zymogens requiring extracellular activation, ST3 is found in the extracellular space as a potentially active mature form, suggesting that the activation of the ST3 proform differs from that of other MMPs. We show in the present study that the ST3 proform is not autocatalytically processed in the presence of 4-aminophenylmercuric acetate (APMA). By using ST3/ST2 chimeras, we demonstrate that resistance to APMA is due to properties associated with both the ST3 pro- and catalytic domains. In agreement with the observation made by Pei and Weiss [Pei and Weiss (1995) Nature (London) 375, 244-247], we find that the requirement for activation of the ST3 proform by the furin convertase is entirely contained within a stretch of 10 amino acids located at the junction between the ST3 pro- and catalytic domains. Furin cleaves human and mouse ST3 equally well. However, PACE-4, a furin-like convertase, is much more efficient on the mouse enzyme, suggesting that ST3 protein determinants other than the conserved Ala-Arg-Asn-Arg-Gln-Lys-Arg sequence preceding the furin cleavage site are implicated in PACE-4 action. Finally, we show that processing of the ST3 proform is inhibited by a furin inhibitor in human MCF7 breast cancer cells stably transfected to constitutively express a full-length human ST3 cDNA. Using brefeldin A, we demonstrate that, in these MCF7 cells, the 56 kDa precursor form of ST3 is post-translationally modified in the cis- or media-Golgi into a 62 kDa proform. Thereafter, its processing into the 47 kDa mature form occurs in the trans-Golgi network and is followed by secretion into the extracellular space.
基质溶解素-3(ST3)是一种基质金属蛋白酶(MMP),与癌症进展以及许多涉及组织重塑的病症有关。与其他以酶原形式分泌需要细胞外激活的MMP不同,ST3以潜在活性成熟形式存在于细胞外空间,这表明ST3前体形式的激活与其他MMP不同。我们在本研究中表明,在乙酸4-氨基苯基汞(APMA)存在下,ST3前体形式不会自动催化加工。通过使用ST3/ST2嵌合体,我们证明对APMA的抗性归因于与ST3前体结构域和催化结构域相关的特性。与裴和魏斯的观察结果一致[裴和魏斯(1995年)《自然》(伦敦)375,244-247],我们发现弗林蛋白酶对ST3前体形式激活的需求完全包含在位于ST3前体结构域和催化结构域交界处的一段10个氨基酸中。弗林蛋白酶对人和小鼠的ST3切割效果相同。然而,PACE-4,一种弗林蛋白酶样转化酶,对小鼠酶的作用效率更高,这表明除了弗林蛋白酶切割位点之前保守的丙氨酸-精氨酸-天冬酰胺-精氨酸-谷氨酰胺-赖氨酸-精氨酸序列之外,ST3蛋白质决定簇也参与了PACE-4的作用。最后,我们表明在稳定转染以组成性表达全长人ST3 cDNA的人MCF7乳腺癌细胞中,弗林蛋白酶抑制剂可抑制ST3前体形式的加工。使用布雷菲德菌素A,我们证明,在这些MCF7细胞中,56 kDa的ST3前体形式在顺式或中高尔基体中进行翻译后修饰,形成62 kDa的前体形式。此后,它在反式高尔基体网络中加工成47 kDa的成熟形式,随后分泌到细胞外空间。